Medication - related osteonecrosis of the jaw (MRONJ) is an adverse side-effect of antiresoptive and antiangiogenic agents. The main clinical sign is exposed necrotic bone in maxillofacial region. Other clinical signs include soft tissue swelling, fistula or purulent inflammation. Tooth extraction is considered a major risk factor for the development of MRONJ. To minimize the risk of MRONJ, patients need to undergo dental treatment before initiating therapy. According to the literature, an invasive dental procedures are recommended to be peformed one month before beginning of the treatment. The purpose of this study was to determine the oral health status and the need for dental treatment in oncological patients prior to the introduction of antiresoptive/antiangiogenic therapy. A retrospective chart analysis of oncologic patients referred for dental treatment prior to the introduction of antiresoptive and / or antiangiogenic therapy was done. Registered data were: age, gender, diagnosis, medication to be introduced, DMFT index, number of teeth to be extracted, type of extraction, antibiotic administration, occurrence of complications, number of arrivals, and time required to obtain the dentist’s consent to initiate therapy. The study involved 22 subjects with an average age of 64 years. The average DMFT index was 18,5. The average number of teeth that needed to be extracted was 3 ± 3 per patient. A small number of cancer patients with metastatic malignancy undergoes dental treatment prior to the introduction of antiresoptive therapy. Most patients require the extraction of one or more teeth. In the majority of patients dental treatment can be completed within 14 days which does not represent significant treatment delay but significantly reduces the risk for MRONJ.